Phase 1 Trial of LVGN7409 (CD40 Agonist Antibody) as Single Agent and Combination Therapies in Advanced or Metastatic Malignancy

Condition:   Cancer Intervention:   Biological: LVGN7409 Sponsor:   Lyvgen Biopharma Holdings Limited Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials